Our participation in the American College of Cardiology 64th annual Scientific Sessions last month in San Diego appears to have been very successful. The traffic to our booth was extremely high and a large number of visitors, from the United States and overseas, expressed interest in our products. Attendees were curious in our core technology EECP® (Enhanced External Counterpulsation) therapy and our growing patient monitoring product line.
Additionally, Dr. Joseph Tartaglia on behalf of his co-authors from the New York Medical College in Valhalia, New York presented a poster abstract on EECP® Therapy and the positive effect it has on decreasing the risk of Major Adverse Cardiac Events (referred to as MACE) for patients. The poster was titled “Patients That Respond to Enhanced External Counterpulsation Are at Decreased Risk for Major Adverse Cardiac Events and Have Increases in Endothelial Precursor Stem Cells”. The study, which followed up on the participating patients for 96 months, demonstrated that these patients had an increase in exercise capacity post treatment and had fewer major adverse cardiac events after treatment. It showed that patients with increased exercise capacity also had an increase in peripheral endothelial precursor CD133+ cells. This suggests, according to the authors, that the new collateral vessel development resulting from the EECP® treatment is responsible for the improved outcomes.
Our next exhibition will be at the Hospitalar meeting in Sao Paulo, Brazil in May. We look forward to showcase our EECP Therapy and our patient monitoring product line to the growing medical industry in Latin America.